Reference : Anti-angiogenic therapy of exudative age-related macular degeneration: current progre...
Scientific journals : Article
Human health sciences : Laboratory medicine & medical technology
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/2268/3845
Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts
English
Noël, Agnès mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
Jost, Maud [ > > ]
Lambert, Vincent mailto [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
Lecomte, Julie mailto [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Rakic, Jean-Marie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
Aug-2007
Trends in Molecular Medicine
Elsevier Sci Ltd
13
8
345-352
Yes (verified by ORBi)
International
1471-4914
Oxford
[en] Age-related macular degeneration (AMD) is the leading cause of blindness in elderly patients. The more aggressive exudative form is characterized by abnormal blood-vessel development that occurs beneath the retina as a result of choroidal neovascularization (CNV). Vascular endothelial growth factor [VEGF) has emerged as the key mediator of CNV formation; this has led to intensive research on VEGF and the recent approval of anti-VEGF compounds by the US Food and Drug Administration. Despite this successful introduction of anti-angiogenic therapies into the clinical setting, there is still a lack of treatments that definitively reverse damaged vision. Here, we consider the importance of putative molecular targets other than VEGF that might have been underestimated. Emerging cellular mechanisms offer additional opportunities for innovative therapeutic approaches.
http://hdl.handle.net/2268/3845
10.1016/j.molmed.2007.06.005
http://www.sciencedirect.com/science/journal/14714914

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Noel trends 2007.pdfAuthor postprint324.55 kBView/Open
Restricted access
Noel A trends2007.pdfPublisher postprint449.8 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.